Idiopathisches Parkinson-Syndrom und Melanom: erhöhte Koinzidenz und Zusammenhang mit L-Dopa?

Zusammenfassung

Der Zusammenhang zwischen Idiopathischen Parkinson-Syndrom (IPS), L-Dopa-Therapie und malignem Melanom wirft weiterhin Fragen auf. Aus diesem Grund wurde von uns eine Studie mit 712 Parkinson-Patienten aus der Klinik und Poliklinik für Neurologie des Universitätsklinikum Hamburg-Eppendorf durchgeführt, die einerseits zeigte, dass IPS-Patienten formal statistisch ein 1-bis zu 4-fach erhöhtes Melanomrisiko haben und andererseits, dass eine L-Dopa-Therapie die Entstehung eines Melanoms nicht ursächlich zu fördern scheint.

Abstract

The relationship between Parkinson's disease (PD), L-dopa therapy and melanoma is still a topic of some controversy. For this reason we have conducted a study with 712 PD patients of the Department of Neurology in the University Hospital Hamburg-Eppendorf. It showed, on the one hand, that PD patients have statistically a 4-times increased risk to develop a melanoma while, on the other hand, that an L-dopa therapy does not promote the development of melanoma.

Schlüsselwörter

IPS und Melanom - IPS - Melanom - L-Dopa

Keywords

Parkinson’s disease and melanoma - Parkinson’s disease - melanoma - L-dopa

• Literatur

• 1 Skibba JL, Pinckley J, Gilbert EF et al. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972; 93: 556-561
• 2 Paisán-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology 2010; 75: 1653-1655
• 3 Siple JF, Schneider DC, Wanlass WA et al. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000; 34: 382-385
• 4 Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence?. Parkinsonism Relat Disord 2003; 9: 321-327
• 5 Rosin MA, Braun 3rd M. Malignant melanoma and levodopa. Cutis 1984; 33: 572-574
• 6 Inzelberg R, Rabey JM, Melamed E et al. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. J Neural Transm 2011; 118: 1199-122075
• 7 Bertoni JM, Arlette JP, Fernandez HH et al; North American Parkinson’s and Melanoma Survey Investigators . Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67: 347-352
• 8 Constantinescu R, Romer M, Kieburtz K. DATATOP Investigators of the Parkinson Study Group . Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 2007; 22: 720-722
• 9 Ferreira JJ, Neutel D, Mestre T et al. Skin cancer and Parkinson’s disease. Mov Disord 2010; 25: 139-148
• 10 Bernstein JE, Medenica M, Soltani K et al. Levodopa administration and multiple primary cutaneous melanomas. Arch Dermatol 1980; 116: 1041-1044
• 11 Schwid SR, Bausch J, Oakes D et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. Mov Disord 2010; 25: 1801-1808
• 12 Lo RY, Tanner CM, Van Den Eeden SK et al. Comorbid cancer in Parkinson’s disease. Mov Disord 2010; 25: 1809-1817
• 13 Sober AJ, Wick MM. Levodopa therapy and malignant melanoma. JAMA 1978; 240: 554-555
• 14 Rigel DS, Patel Z, Bolognia J et al. Evaluation of Parkinson’s disease (PD) prevalence in patients with malignant melanoma. Mov Disord 2006; 21: S58
• 15 Baade PD, Fritschi L, Freedman DM. Mortality due to Amyotrophic Lateral Sclerosis and Parkinson’s Disease among Melanoma Patients. Neuroepidemiology 2007; 28: 16-20
• 16 Garbe C. Therapiekonzepte Onkologie-Malignes Melanom. In: Seeber S, Schütte J. Hrsg Berlin-Heidelberg: Springerverlag; 2003: 1057-1087
• 17 Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648
• 18 Katzenschlager R, Head J, Schrag A et al; Parkinson’s Disease Research Group of the United Kingdom . Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480
• 19 Mutch WJ, Dingwall-Fordyce I, Downie AW et al. Parkinson’s disease in a Scottish city. Br Med J (Clin Res Ed) 1986; 292: 534-536
• 20 Hughes AJ, Daniel SE, Blankson S et al. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993; 50: 140-148
• 21 Alves G, Müller B, Herlofson K et al; Norwegian ParkWest study group . Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009; 80: 851-857
• 22 Martilla RJ. Epidemiology. In: Handbook of Parkinson’s disease. 2. Auflage. Koller WC. Hrsg New York: Marcel Dekker Incl; 1992: 35-37
• 23 Gehlen W. Stammganglienerkrankungen. In: Neurologie. Fröscher W. Hrsg Berlin: de Gruyter; 1991: 368-382
• 24 Zhang ZX, Román GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 1993; 12: 195-208
• 25 de Rijk MC, Launer LJ, Berger K et al. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21-S23
• 26 Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022
• 27 Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280-290
• 28 de Vries E, Bray FI, Coebergh JW et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126
• 29 Garbe C, Hauschild A, Volkenandt M et al. Leitlinie Malignes Melanom. Vers. 15, 02/2005
• 30 Vollmer RT, Seigler HF. Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. Am J Clin Pathol 2001; 115: 205-212
• 31 Owen SA, Sanders LL, Edwards LJ et al. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. Cancer 2001; 91: 983-991
• 32 Garbe C, Büttner P, Ellwanger U et al. Das Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft in den Jahren 1983–1993. Hautarzt 1995; 46: 683-692
• 33 Elsaesser O, Leiter U, Buettner PG et al. Prognosis of sentinel node staged patients with primary cutaneous melanoma. PLoS One 2012; 7: e29791
• 34 Balch CM, Gershenwald JE, Soong SJ et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452-2459
• 35 Krebsregister Hamburg. Melanome der Haut. http://www.krebsregister-hamburg.de/index.php 10.05.2011
• 36 Robert Koch Institut. Krebs in Deutschland 2007/2008. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2012/krebs_in_deutschland_2012.pdf?__blob=publicationFile Stand: 04.04.2012
• 37 Statistisches Bundesamt. https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Bevoelkerungsstand/Tabellen/­GeschlechtStaatsangehoerigkeit.html Stand: 04.04.2012
• 38 Liu R, Gao X, Lu Y et al. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76: 2002-2009
• 39 Driver JA, Logroscino G, Buring JE et al. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 2007; 16: 1260-1265
• 40 Rugbjerg K, Friis S, Lassen CF et al. Malignant melanoma, breast cancer and other cancers in patients with Parkinson disease. Int J Cancer 2012; 131: 1904-1911
• 41 Vermeij JD, Winogrodzka A, Trip J et al. Parkinson’s disease, levodopa-use and the risk of melanoma. Parkinsonism Relat Disord 2009; 15: 551-553
• 42 Olsen JH, Tangerud K, Wermuth L et al. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007; 22: 1252-1257
• 43 Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol 1985; 17: 505-509
• 44 Sun LM, Liang JA, Chang SN et al. Analysis of Parkinson’s disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. Neuroepidemiology 2011; 37: 114-119